๐ฐ Genmaba S News
Genmaba S News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genmaba S. Real-time updates on events, politics, business and more.
May 6, 2024
Vestmark Advisory Solutions Inc. raised its stake in Genmab A/S (NASDAQ:GMAB – Free Report) by 28.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,656 shares of the company’s stock after buying an additional 7,905 shares during the period. Vestmark […]
May 1, 2024
Genmab A/S (NASDAQ:GMAB – Get Free Report) is scheduled to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.16 per share for the quarter. Genmab A/S has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call […]
April 19, 2024
Genmab A/S (NASDAQ:GMAB – Get Free Report) has been given a consensus rating of “Hold” by the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have issued a buy recommendation on […]
April 9, 2024
Genmab A/S (NASDAQ:GMAB – Free Report) – Investment analysts at William Blair dropped their FY2025 earnings per share (EPS) estimates for shares of Genmab A/S in a research report issued to clients and investors on Wednesday, April 3rd. William Blair analyst M. Phipps now expects that the company will post earnings per share of $1.07 […]
April 8, 2024
HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB – Free Report) in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has a $50.00 target price on the stock. Other equities analysts have also issued research reports about the company. Morgan Stanley reaffirmed an underweight rating on […]
April 4, 2024
Investors might not have been overly excited, but Genmab A/S executives enthused about the โcomplementarityโ of its proposed acquisition of antibody-drug conjugate (ADC) specialist Profoundbio Inc. for $1.8 billion in cash. The deal, expected to close in the first half of 2024, marks the biggest by far for the Copenhagen, Denmark-based biopharma and the latest transaction for the red hot ADC space.
April 4, 2024
Genmab A/S (NASDAQ:GMAB – Get Free Report)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $29.30, but opened at $30.32. Genmab A/S shares last traded at $30.41, with a volume of 35,398 shares traded. Analysts Set New Price Targets Several research analysts have recently weighed in […]
April 3, 2024
Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in...
March 29, 2024
Truist Financial restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB – Free Report) in a report released on Tuesday morning, Benzinga reports. Truist Financial currently has a $50.00 target price on the stock. GMAB has been the subject of several other reports. Citigroup lowered Genmab A/S from a neutral rating to a sell […]
March 27, 2024
Genmab A/S (NASDAQ:GMAB – Get Free Report) has received a consensus recommendation of “Hold” from the thirteen ratings firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and eight have issued a buy recommendation on the company. The average […]